Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24211
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hall, S. | - |
dc.contributor.author | Mease, P. | - |
dc.contributor.author | Kavanaugh, A. | - |
dc.contributor.author | Reimold, A. | - |
dc.contributor.author | Tahir, H. | - |
dc.contributor.author | Rech, J. | - |
dc.contributor.author | GEUSENS, Piet | - |
dc.contributor.author | Pascale, P. | - |
dc.contributor.author | Delicha, E. | - |
dc.contributor.author | Pricop, L. | - |
dc.contributor.author | Mpofu, S. | - |
dc.date.accessioned | 2017-08-11T10:22:47Z | - |
dc.date.available | 2017-08-11T10:22:47Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | INTERNAL MEDICINE JOURNAL, 47, p. 37-38 (Art N° P90) | - |
dc.identifier.issn | 1444-0903 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24211 | - |
dc.description.abstract | Secukinumab, an anti–interleukin-17A monoclonal antibody, provided rapid and significant improvements in the key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326) with improvements sustained through 2 years. Here, we present efficacy and safety results through 3 years in the extension of the FUTURE 1 study. | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis (PSA) through 3 years: efficacy and safety results from a phase 3 trial | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 38 | - |
dc.identifier.spage | 37 | - |
dc.identifier.volume | 47 | - |
local.format.pages | 2 | - |
local.bibliographicCitation.jcat | M | - |
dc.description.notes | [Hall, S.] Monash Univ, Melbourne, Vic, Australia. [Mease, P.] Swedish Med Ctr, Seattle, WA USA. [Mease, P.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, A.] Univ Calif San Diego, Sch Med, La Jolla, CA USA. [Reimold, A.] Dallas VA Med Ctr, Dallas, TX USA. [Reimold, A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, H.] Barts Hlth NHS Trust, London, England. [Rech, J.] Friedrich Alexander Univ Erlangen Narnberg Fau, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol, Erlangen, Germany. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Geusens, P.] Maastricht Univ Hosp, Maastricht, Netherlands. [Pascale, P.; Delicha, E.; Mpofu, S.] Novartis Pharma Ag, Basel, Switzerland. [Pricop, L.] Novartis Pharmaceut, E Hanover, NJ USA. | - |
local.publisher.place | HOBOKEN | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
local.bibliographicCitation.artnr | P90 | - |
dc.identifier.isi | 000400304400113 | - |
dc.identifier.url | http://acrabstracts.org/abstract/secukinumab-provides-sustained-improvements-in-the-signs-and-symptoms-of-active-psoriatic-arthritis-through-3-years-efficacy-and-safety-results-from-a-phase-3-trial/ | - |
item.accessRights | Open Access | - |
item.fullcitation | Hall, S.; Mease, P.; Kavanaugh, A.; Reimold, A.; Tahir, H.; Rech, J.; GEUSENS, Piet; Pascale, P.; Delicha, E.; Pricop, L. & Mpofu, S. (2017) Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis (PSA) through 3 years: efficacy and safety results from a phase 3 trial. In: INTERNAL MEDICINE JOURNAL, 47, p. 37-38 (Art N° P90). | - |
item.fulltext | With Fulltext | - |
item.contributor | Hall, S. | - |
item.contributor | Mease, P. | - |
item.contributor | Kavanaugh, A. | - |
item.contributor | Reimold, A. | - |
item.contributor | Tahir, H. | - |
item.contributor | Rech, J. | - |
item.contributor | GEUSENS, Piet | - |
item.contributor | Pascale, P. | - |
item.contributor | Delicha, E. | - |
item.contributor | Pricop, L. | - |
item.contributor | Mpofu, S. | - |
crisitem.journal.issn | 1444-0903 | - |
crisitem.journal.eissn | 1445-5994 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
acrabstracts_org_abstract_secukinumab_provides_sustained_imp.pdf | Published version | 65.7 kB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.